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Background
Signaling via the nitric oxide (NO) – soluble guanylate
cyclase (sGC) – cyclic guanosine monophosphate (cGMP)
pathway is frequently impaired in cardiovascular disease
states providing a rationale for enhancing it pharmacolog-
ically. Nitrovasodilators have been used for more than a
century to induce vasodilation via the sGC-cGMP path-
way; however, the development of tolerance and poten-
tially adverse cGMP-independent actions of
nitrovasodilators such as promoting oxidative stress and
protein modification are functionally important limita-
tions. BAY 58–2667 is a novel, NO-independent sGC acti-
vator which is not associated with the development of
tolerance and which preferentially activates oxidized or
heme-free sGC, which both are insensitive to endogenous
NO and nitrovasodilators [1,2]. In this study we sought to
define the cardiorenal actions of BAY 58–2667 as com-
pared to nitroglycerin (NTG) in experimental heart failure
(HF). We hypothesized that BAY 58–2667 would potently
unload the heart and preserve renal function in a canine
model of HF in a manner similar to NTG.
Methods and results
HF was induced by rapid ventricular pacing. After 10 days
of pacing, cardiorenal and humoral function were
assessed in an acute study at baseline and with adminis-
tration of 2 doses of BAY 58–2667 (0.1 and 0.3 μg/kg/
min; n = 7) or NTG (1 and 5 μg/kg/min; n = 6). *p < 0.05
vs. respective baseline. Administration of 0.3 ug/kg/min
BAY 58–2667 reduced mean arterial pressure (97 ± 7 to 68
± 5* mmHg), right atrial pressure (6.7 ± 1.1 to 3.4 ± 0.7*
mmHg), pulmonary artery pressure (24 ± 1 to 18 ± 1*
mmHg), pulmonary capillary wedge pressure (19 ± 1 to
12 ± 2* mmHg), as well as systemic and renal vascular
resistance*. Cardiac output (2.4 ± 0.3 to 3.2 ± 0.4* L/min)
and renal blood flow (165 ± 14 to 218 ± 16* mL/min)
increased. Glomerular filtration rate was maintained
without activation of plasma renin activity, angiotensin II,
or aldosterone. In a qualitative comparison, NTG medi-
ated similar hemodynamic and humoral changes.
Conclusion
The novel sGC activator BAY 58–2667 potently unloads
the heart, increases cardiac output, and preserves glomer-
ular filtration rate without activation of the renin-angi-
otensin-aldosterone system in experimental CHF. These
beneficial properties make direct sGC activation with BAY
58–2667 a promising new strategy for the treatment of
cardiovascular diseases such as HF. These findings also
support the presence of oxidized or heme-free sGC in HF.
Furthermore, as the acute hemodynamic actions of BAY
58–2667 and NTG were qualitatively similar, these find-
ings suggest that these beneficial actions are mediated by
cGMP signaling rather than cGMP-independent path-
ways. Potential differences in the long-term effects of BAY
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58–2667 as compared to nitrovasodilators remain to be
investigated.
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